$43.140
+0.375 (+0.87%)Zum Schluss
TRAX im Vergleich zur Peergroup
In the context of the broader market, TRAX competes directly with industry leaders such as KARD and TYRA. With a market capitalization of $1.55B, it holds a leading position in the sector. When comparing efficiency, TRAX's gross margin of N/A stands against KARD's N/A and TYRA's N/A. Such benchmarking helps identify whether First Tracks Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von First Tracks Biotherapeutics Inc
The company has experienced significant losses, with a net income of -33,374,000 USD in Q2 2026 and an EPS of -0.95. However, the current ratio has improved to 14.28, indicating better liquidity.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.